The clinical demand for in vitro diagnostics (IVDs) continues to grow, from biomarkers informing the rapid treatment of trauma and combating antimicrobial resistance, to blood tests diagnosing dementia or delivering personalised medicine.
Many organisations across the healthcare spectrum contribute to the development and implementation of IVDs. To explore this pathway, and identify where NHS laboratory professionals might contribute, the NIHR Clinical Research Network (CRN) West Midlands recently sponsored a symposium organised by the West Midlands Laboratory Medicine Research Group.
The meeting brought together over 70 delegates from clinical laboratories across the UK and representatives from industry and academia to discuss IVD development pathways.
Speakers were invited from some of the organisations involved to discuss their roles and open the door to ways in which they can, and do, work with NHS laboratory professionals. Among these was Lucy Chatwin, Business Manager at WMAHSN, who described the role of the AHSNs in providing a catalyst to generate adoption of innovations. One of WMAHSN's priorities is advanced diagnostics, genomics and precision medicine, and Lucy introduced delegates to Abdullah Sabyah from Rightangled Diagnostics, with whom they had worked to develop and implement genomic diagnostic technology within cardiology.
In addition, the formal presentations were concluded by Sean James, Genomics Ambassador for the West Midlands Genomic Medicine Centre, who gave an update on the 100,000 Genomes Project and its role in generating future diagnostic pathways.
To read more about the event, please visit the Biomedical Scientist website for a full report from Dr Owen Driskell, is a Clinical Scientist and Lead for Laboratory Medicine at the CRN West Midlands, and Ian Davies, Biomedical Scientist and Healthcare Science Course Leader at Staffordshire University.